

EXHIBIT 32

Exhibit 5
Moderna Agreements Summary¹

Licensor	Licensee	Date	Agreement Title	Includes Rights to Patents-in-Suit	Territory	License/Agreement Type	Payments	Amendments and Related Documents
<u>Moderna-Acuitas Agreements</u>								
[1] Moderna/Acuitas	Moderna/Acuitas	7/3/14	Development and Option Agreement	Yes	Worldwide	Acuitas to Moderna: • Non-exclusive license for technology evaluation purposes Moderna to Acuitas: • Non-exclusive license for technology evaluation purposes	Moderna to Acuitas: • Annual fees • Option exercise fee	
[2] Acuitas	Moderna	5/22/15	Non-Exclusive License Agreement	Yes	Worldwide	• Non-exclusive license with commercial rights	• Development/commercial milestones • Running royalties (%)	
[3] Acuitas	Moderna	8/19/16	Non-Exclusive License Agreement	Yes	Worldwide	• Non-exclusive license with commercial rights	• Development/commercial milestones • Running royalties (%)	
[4] Acuitas	Moderna	10/12/16	Non-Exclusive License Agreement	Yes	Worldwide	• Non-exclusive license with commercial rights	• Development/commercial milestones • Running royalties (%)	
[5] Acuitas	Moderna	12/14/16	Non-Exclusive License Agreement	No	Worldwide	• Non-exclusive license with commercial rights	• Development/commercial milestones • Running royalties (%)	
<u>Moderna-Merck Agreements</u>								
[6] Moderna	Merck	1/12/15	Master Collaboration and License Agreement	No	Worldwide	• Exclusive license with commercial rights	• Upfront fee • Development/commercial milestones • Running royalties (%)	• MRNA-GEN-00456809: First Amendment • MRNA-GEN-00456802: Second Amendment • MRNA-GEN-00456791: Third Amendment • MRNA-GEN-00457190: Fourth Amendment • MRNA-GEN-00457386: Term Extension Letter • MRNA-GEN-00456816: Fifth Amendment • MRNA-GEN-00456772: Termination Agreement
[7] Merck	Moderna	1/12/15	Sublicense Agreement	No	Worldwide	• Non-exclusive sublicense and license with commercial rights	Not specified	
[8] Moderna/Merck	Moderna/Merck	4/17/18	Amended and Restated mRNA Cancer Vaccine Collaboration and License Agreement	No	Worldwide	Merck to Moderna: • Co-exclusive license for manufacturing purposes Moderna to Merck: • Co-exclusive license for research and development	Merck to Moderna: • Upfront fee (previously paid) • Participation election payment • Profit/loss sharing (%)	
<u>Moderna-AstraZeneca Agreements</u>								
[9] Moderna/AstraZeneca	Moderna/AstraZeneca	1/11/16	Strategic Drug Development Collaboration and License Agreement	No	Worldwide	AstraZeneca to Moderna: • Co-exclusive license solely for activities under the applicable Discovery Program • Co-exclusive license with commercial rights Moderna to AstraZeneca: • Co-exclusive license solely for activities under the applicable Discovery Program • Co-exclusive license with commercial rights	AstraZeneca to Moderna: • Running royalties (%) • Profit and loss share for U.S. commercialization activities (%) Moderna to AstraZeneca: • Running royalty on Declined Product (%)	
[10] Moderna/AstraZeneca	Moderna/AstraZeneca	10/31/17	Collaboration and License Agreement	No	Worldwide	AstraZeneca to Moderna: • Co-exclusive license solely for activities under the applicable Discovery Program • Co-exclusive license with commercial rights Moderna to AstraZeneca: • Co-exclusive license solely for activities under the applicable Discovery Program • Co-exclusive license with commercial rights	AstraZeneca to Moderna: • Running royalties (%) • Profit and loss share for U.S. commercialization activities (%)	

Exhibit 5
Moderna Agreements Summary¹

	Licensor	Licensee	Date	Agreement Title	Includes Rights to Patents-In-Suit	Territory	License/Agreement Type	Payments	Amendments and Related Documents
[11]	Moderna	AstraZeneca	6/15/18	Amended and Restated Services and Collaboration Agreement	No	Not specified	• Services agreement to identify research polypeptides and mRNA constructs	• Upfront fee	
[12]	Moderna	AstraZeneca	6/15/18	Amended and Restated Option Agreement	No	Worldwide	• Co-exclusive license for manufacturing purposes • Exclusive license for all other exploitation of collaboration constructs in the applicable field	• Option exercise fee • Product candidate purchase fee	
[13]	Moderna	AstraZeneca	9/23/19	Patent Sublicense Agreement	No	Worldwide	• Sublicense with commercial rights	• Development/commercial milestones • Running royalties (%)	
<u>Moderna-Alexion Agreements</u>									
[14]	Moderna	Alexion	1/13/14	Services and Collaboration Agreement	No	Worldwide	• Services agreement to assist Alexion in evaluating option	N/A	
[15]	Moderna	Alexion	1/13/14	Option Agreement	No	Worldwide	• Exclusive license option for development and commercialization	• Option exercise fee	
<u>Moderna-Chiesi Agreements</u>									
[16]	Moderna	Chiesi	9/16/20	Collaboration and License Agreement	No	Worldwide	• Co-exclusive license for research • Exclusive license with commercial rights	• Upfront fee • Technology access fee • Option exercise fee • Development/commercial milestones • Running royalties (%)	
[17]	Moderna	Chiesi	10/14/21	Patent Sublicense Agreement	No	Worldwide	• Non-exclusive sublicense with commercial rights	• Development/commercial milestones	
<u>Moderna-Vertex Agreements</u>									
[18]	Moderna	Vertex	7/1/16	Strategic Collaboration and License Agreement	No	Worldwide	• Exclusive license with commercial rights	• Upfront fee • Development milestones • Running royalties (%)	
[19]	Moderna	Vertex	9/16/20	Strategic Collaboration and License Agreement	No	Worldwide	• Exclusive license with commercial rights	• Upfront fee • Development/commercial milestones • Running royalties (%)	
<u>Other Agreements</u>									
[20]									
[21]	Cellscript	Moderna	6/26/17	Patent Sublicense Agreement	No	Worldwide	• Non-exclusive sublicense with commercial rights	• Upfront fee & license maintenance fees • Development/commercial milestones • Running royalties (%)	
[22]	NIAID	Moderna	12/14/22	Patent License Non-Exclusive	No	Worldwide	• Non-exclusive license with commercial rights	• Upfront fee • Development/commercial milestones • Annual royalties • Running royalties (%)	
[23]	CytomX	Moderna	12/30/22	Collaboration and License Agreement	No	Worldwide	• Exclusive license with commercial rights	• Upfront fee • Development candidate selection fee • Development/commercial milestones • Running royalties (%)	• MRNA-GEN-00457387: Letter Agreement

Exhibit 5
Moderna Agreements Summary¹

	Licensor	Licensee	Date	Agreement Title	Includes Rights to Patents-in-Suit	Territory	License/Agreement Type	Payments	Amendments and Related Documents
[24]	Life Edit	Moderna	2/21/23	Strategic Collaboration and License Agreement	No	Worldwide	<ul style="list-style-type: none"> • Non-exclusive license for research • Exclusive license option with commercial rights 	<ul style="list-style-type: none"> • Upfront fee & research payment • Development/commercial milestones • Running royalties (%) 	
[25]	Generation Bio	Moderna	3/23/23	Collaboration and License Agreement	No	Worldwide	<ul style="list-style-type: none"> • Exclusive license with commercial rights 	<ul style="list-style-type: none"> • Upfront fee • Option exercise fee • Development/commercial milestones • Running royalties (%) 	

Note:

1. This list of Moderna agreements combines agreements deemed relevant by Plaintiffs and Moderna in their Interrogatory Responses. Specifically, I compile the agreements based on Plaintiff Genevant Sciences GmbH's Tenth Supplemental Responses and Objections to Defendants Moderna, Inc. and ModernaTX, Inc.'s First Set of Interrogatories (No. 5), Plaintiff Arbutus Biopharma Corporation's Corrected and Supplemental Responses and Objections to Defendants Moderna, Inc. and ModernaTX, Inc.'s First Set of Interrogatories (Nos. 3 & 7), and Defendants' Fourteenth Supplemental Objections and Responses to Plaintiffs' First Set of Interrogatories (Nos. 1-10), as well as Lawton Report, Schedule 6.3.

Sources:

[1]: MRNA-GEN-00225558
[2]: GENV-00021315
[3]: GENV-00021083
[4]: GENV-00021199
[5]: GENV-00021427
[6]: MRNA-GEN-00457212
[7]: MRNA-GEN-00457194
[8]: MRNA-GEN-00456830
[9]: MRNA-GEN-00458197
[10]: MRNA-GEN-00457628
[11]: MRNA-GEN-00458389
[12]: MRNA-GEN-00458838
[13]: MRNA-GEN-00457389
[14]: MRNA-GEN-00458495
[15]: MRNA-GEN-00457811
[16]: MRNA-GEN-00457979
[17]: MRNA-GEN-00458160
[18]: MRNA-GEN-00458927
[19]: MRNA-GEN-00457429
[20]: MRNA-GEN-01237004
[21]: MRNA-GEN-00457584
[22]: MRNA-GEN-00459173
[23]: MRNA-GEN-00459066
[24]: MRNA-GEN-00458590
[25]: MRNA-GEN-02654081